A PHASE IIA MULTICENTER OPEN-LABEL STUDY TO ASSESS THE SAFETY AND EFFICACY OF THE COMBINATION OF BL-8040 AND PEMBROLIZUMAB IN SUBJECTS WITH METASTATIC PANCREATIC CANCER THE COMBAT STUDY

Brief description of study

The purpose of this clinical study is to learn if BL-8040 given alone followed by combination with pembrolizumab (KEYTRUDA®) and chemotherapy of Onivyde® + 5-FU/LV is safe and effective in treating patients with unresectable metastatic pancreatic cancer. Additional goals of this study are to better understand the mechanism of action of BL-8040.You are being asked to participate in this study because you have been diagnosed with unresectable metastatic pancreatic cancer.


Clinical Study Identifier: s18-01955
ClinicalTrials.gov Identifier: NCT02826486
Principal Investigator: Paul E. Oberstein
Currently Recruiting

Contact the research team to learn more about this study.


By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.